All In Biotech

Drug Trial Radar · NCT07213349

Daridorexant for Alzheimer Disease Prevention

Double Blind Clinical Trial of Daridorexant (Dual Orexin Receptor Antagonist) for Alzheimer Disease Prevention

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 14, 2025

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Douglas Mental Health University InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Weston Family Foundation
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.

Conditions

  • Alzheimer Disease (AD)

Interventions

  • Daridorexant 50 mgDrug

    Study drug (Daridorexant 50 mg) taken orally each night 30 minutes before bedtime, for the 1 year duration of the study

  • PlaceboDrug

    Study drug (Placebo) will be taken orally each night, 30 minutes before bedtime, for the 1 year duration of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in plasma p-tau217/np-tau217 ratioTime frame: baseline up to estimated 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre StoP-Alzheimer (Douglas Mental Health University Institute - Research Centre)

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.